Literature DB >> 32104573

PRO: Patients With Chronic Hepatitis B in Immune-Tolerant Phase Should Be Treated.

Jagpal Singh Klair1, James Vancura1, Arvind R Murali1.   

Abstract

Entities:  

Year:  2020        PMID： 32104573      PMCID： PMC7041956          DOI： 10.1002/cld.892

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  10 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

3.  Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; C S Chien
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

Authors:  Patrick T F Kennedy; Elena Sandalova; Juandy Jo; Upkar Gill; Ines Ushiro-Lumb; Anthony T Tan; Sandhia Naik; Graham R Foster; Antonio Bertoletti
Journal:  Gastroenterology       Date:  2012-06-15       Impact factor: 22.682

5.  HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.

Authors:  William S Mason; Upkar S Gill; Samuel Litwin; Yan Zhou; Suraj Peri; Oltin Pop; Michelle L W Hong; Sandhia Naik; Alberto Quaglia; Antonio Bertoletti; Patrick T F Kennedy
Journal:  Gastroenterology       Date:  2016-07-22       Impact factor: 22.682

6.  The clinical significance of persistently normal ALT in chronic hepatitis B infection.

Authors:  Michelle Lai; Benjamin J Hyatt; Imad Nasser; Michael Curry; Nezam H Afdhal
Journal:  J Hepatol       Date:  2007-09-24       Impact factor: 25.083

7.  Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.

Authors:  Manoj Kumar; Shiv K Sarin; Syed Hissar; Chandana Pande; Puja Sakhuja; Barjesh Chander Sharma; Ranjit Chauhan; Sujoy Bose
Journal:  Gastroenterology       Date:  2008-02-29       Impact factor: 22.682

8.  No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

Authors:  Kathryn M Kitrinos; Amoreena Corsa; Yang Liu; John Flaherty; Andrea Snow-Lampart; Patrick Marcellin; Katyna Borroto-Esoda; Michael D Miller
Journal:  Hepatology       Date:  2014-02       Impact factor: 17.425

9.  Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.

Authors:  Young Chang; Won Hyeok Choe; Dong Hyun Sinn; Jeong-Hoon Lee; Sang Hoon Ahn; Hyewon Lee; Jae-Jun Shim; Dae Won Jun; Soo Young Park; Joon Yeul Nam; Eun Ju Cho; Su Jong Yu; Dong Ho Lee; Jeong Min Lee; Yoon Jun Kim; So Young Kwon; Seung Woon Paik; Jung-Hwan Yoon
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

10.  A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.

Authors:  Wai-Kay Seto; Ching-Lung Lai; Philip P C Ip; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; Ivan Fan-Ngai Hung; Man-Fung Yuen
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240
  10 in total
  1 in total

1.  Domestic cat hepadnavirus associated with hepatopathy in cats: A retrospective study.

Authors:  Chutchai Piewbang; Wichan Dankaona; Panida Poonsin; Jakarwan Yostawonkul; Sitthichok Lacharoje; Sirintra Sirivisoot; Tanit Kasantikul; Padet Tummaruk; Somporn Techangamsuwan
Journal:  J Vet Intern Med       Date:  2022-08-24       Impact factor: 3.175
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.